Research analysts covering Inspira Technologies OXY B.H.N..
Recent press releases and 8-K filings for IINN.
Inspira Technologies Announces Pricing of $4.75 Million Registered Direct Offering
IINN
- Inspira Technologies OXY B.H.N. Ltd. announced a registered direct offering and concurrent private placement of securities, expected to close on or about February 6, 2026.
- The offering includes the sale of an aggregate of 6,785,715 ordinary shares (or equivalents) at a purchase price of $0.70 per share, with expected gross proceeds of approximately $4.75 million.
- In the concurrent private placement, unregistered warrants to purchase up to 6,785,715 ordinary shares will be issued, with an exercise price of $0.70 per share, exercisable six months after issuance, and expiring five and a half years from issuance.
- The company intends to use the net proceeds from the offering for working capital and general corporate purposes.
- Additionally, existing warrants issued in December 2023 for 3,031,250 ordinary shares had their exercise price reduced from $1.28 to $0.70 per share and their expiration date extended to February 5, 2031.
16 hours ago
Inspira Technologies Announces Registered Direct Offering and Private Placement
IINN
- Inspira Technologies has entered into a definitive agreement for a registered direct offering of 6,785,715 ordinary shares at a purchase price of $0.70 per share, expecting to generate approximately $4.75 million in gross proceeds.
- Concurrently, the company will issue and sell 6,785,715 unregistered warrants in a private placement, with an exercise price of $0.70 per share.
- The offering is anticipated to close on or about February 6, 2026, with net proceeds intended for working capital and general corporate purposes.
- Certain existing warrants issued to an investor in December 2023, for up to 3,031,250 ordinary shares, will be amended to reduce their exercise price from $1.28 to $0.70 per share.
1 day ago
Inspira Technologies Validates Standalone HYLA™ Blood Sensor with Clinical-Grade Accuracy
IINN
Product Launch
New Projects/Investments
- Inspira Technologies announced the successful validation of its Next-Generation Standalone HYLA™ System, which achieved 94.2% accuracy for the continuous optical measurement of Partial Pressure of Carbon Dioxide (pCO₂).
- This standalone configuration allows the company to penetrate the broader $48 billion heart-lung surgery market immediately upon clearance, independent of its existing life-support hardware.
- The strategy expands Inspira Technologies’ total addressable market and activates a high-margin, recurring revenue model through disposable optical sensors and modular software upgrades.
- The company is moving rapidly toward its planned U.S. Food and Drug Administration ("FDA") regulatory submission process in 2026 for the HYLA system.
4 days ago
Inspira Technologies' ART100 Completes Clinical Evaluation and Enters Budgeted Procurement
IINN
New Projects/Investments
Revenue Acceleration/Inflection
- Inspira Technologies' FDA-cleared INSPIRA™ ART100 system has completed its clinical evaluation and entered a budgeted procurement process at a leading U.S. academic medical center.
- This marks the first instance at a major U.S. academic medical center where the ART100 has progressed from clinical evaluation to a formal, budgeted procurement pathway.
- The medical center has initiated an internal procurement process for the acquisition of multiple ART100 systems, following the successful treatment of approximately 30 patients.
- The Company believes this milestone significantly strengthens its U.S. commercial positioning and supports broader adoption of the ART100 platform.
Jan 29, 2026, 1:30 PM
Inspira Technologies' ART100 System Completes Clinical Evaluation and Enters Budgeted Procurement
IINN
Product Launch
- Inspira Technologies' FDA-cleared INSPIRA ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center.
- This marks the first instance at a major U.S. academic medical center where the ART100 has progressed from clinical evaluation to a formal, budgeted procurement pathway.
- After successfully treating approximately 30 patients, the ART100 systems have been incorporated into the medical center's routine workflow, with the clinical decision-making phase fully concluded.
- CEO Dagi Ben-Noon stated that this milestone is a powerful validation of the ART100's clinical value, reliability, and real-world commercial readiness.
Jan 29, 2026, 1:30 PM
Inspira Technologies' Binding Purchase Orders Advance to Final Budgetary Stage
IINN
New Projects/Investments
Guidance Update
- Inspira Technologies' $22.5 million and $27 million binding purchase orders have advanced to the final budgetary validation and fund allocation stage within governmental authorities' procurement processes.
- Approximately 91% of these purchase orders have cleared commercial and administrative review stages, representing the concluding administrative step before fund release and operational execution.
- Payment and revenue recognition related to these purchase orders are expected during the 2026 fiscal cycle.
Jan 21, 2026, 1:50 PM
Inspira Technologies Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion
IINN
M&A
New Projects/Investments
Guidance Update
- Inspira Technologies has outlined a strategic vision and transaction framework for expanding into breast cancer liquid biopsy diagnostics, which includes the acquisition of an advanced liquid biopsy platform and a concurrent $15 million equity investment.
- The acquisition of the liquid biopsy business is expected to be in exchange for up to 40% of Inspira's issued and outstanding share capital on a fully diluted basis.
- The $15 million equity investment, at a pre-money valuation of $180 million, will allocate up to $12 million to support Inspira's existing respiratory and blood-monitoring operations.
- To preserve shareholder value, a Contingent Value Rights (CVR) framework is planned, designed to exclusively allocate future value from the company's current respiratory and life-support technologies to existing shareholders.
- The liquid biopsy platform, initially focused on breast cancer, analyzes intact circulating tumor cells from blood samples and has demonstrated a high degree of concordance with traditional tissue biopsy in preliminary clinical validation.
Jan 8, 2026, 9:01 PM
Inspira Technologies Outlines Strategic Expansion into Liquid Biopsy Diagnostics
IINN
M&A
New Projects/Investments
- Inspira Technologies is undertaking a strategic expansion into liquid biopsy diagnostics, which involves a proposed acquisition of an advanced liquid biopsy platform and a concurrent equity investment.
- The liquid biopsy platform is designed to analyze intact circulating tumor cells (CTCs) from blood samples, with an initial clinical focus on breast cancer.
- The transaction includes a $15 million equity investment at a pre-money valuation of $180 million, with up to $12 million of this funding allocated to support Inspira's existing respiratory and blood-monitoring operations.
- To preserve shareholder value for the existing respiratory and life-support business, current shareholders are expected to receive Contingent Value Rights (CVRs).
Jan 8, 2026, 1:50 PM
Inspira Technologies Announces Term Sheet for Acquisition and $15 Million Equity Investment
IINN
M&A
New Projects/Investments
- Inspira Technologies has signed a non-binding term sheet for a two-part transaction: the acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment.
- The $15 million equity investment is based on a pre-money valuation of $180 million, which the company believes reflects a significant premium over its current market capitalization.
- The acquisition will enable Inspira to enter the rapidly growing liquid biopsy market, projected to reach $58 billion over the coming decade, with an initial clinical focus on breast cancer.
- A shareholder protection framework is included, providing contingent value rights to existing shareholders to preserve their full economic upside from Inspira’s current respiratory and blood monitoring technologies.
Jan 5, 2026, 3:46 PM
Inspira Technologies Signs Term Sheet for Liquid Biopsy Acquisition and $15 Million Investment
IINN
M&A
New Projects/Investments
- Inspira Technologies has entered into a non-binding term sheet for a two-part transaction that includes the acquisition of an advanced liquid biopsy diagnostics business and a concurrent $15 million strategic equity investment.
- The $15 million equity investment is based on a pre-money valuation of the Company of $180 million, which the Company believes reflects a significant premium over its current market capitalization.
- Inspira intends to allocate $12 million of the investment proceeds to fund the continued operations and development of its existing respiratory and blood monitoring technologies.
- A shareholder protection framework is included in the proposed transaction, designed to preserve the full economic upside of Inspira's existing respiratory and blood-monitoring platforms for current shareholders through contingent value rights.
Jan 5, 2026, 2:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more